JP2024532807A - 重水素化化合物 - Google Patents

重水素化化合物 Download PDF

Info

Publication number
JP2024532807A
JP2024532807A JP2024508768A JP2024508768A JP2024532807A JP 2024532807 A JP2024532807 A JP 2024532807A JP 2024508768 A JP2024508768 A JP 2024508768A JP 2024508768 A JP2024508768 A JP 2024508768A JP 2024532807 A JP2024532807 A JP 2024532807A
Authority
JP
Japan
Prior art keywords
compound
less
pharma
acceptable salt
ceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024508768A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532807A5 (https=
Inventor
シュウ，チューシャン
ティアン，ジン
Original Assignee
アレバンド ファーマシューティカルズ（ホンコン）リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレバンド ファーマシューティカルズ（ホンコン）リミテッド filed Critical アレバンド ファーマシューティカルズ（ホンコン）リミテッド
Publication of JP2024532807A publication Critical patent/JP2024532807A/ja
Publication of JP2024532807A5 publication Critical patent/JP2024532807A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2024508768A 2021-08-13 2022-08-09 重水素化化合物 Pending JP2024532807A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/112521 2021-08-13
CN2021112521 2021-08-13
CN2022106648 2022-07-20
CNPCT/CN2022/106648 2022-07-20
PCT/CN2022/111089 WO2023016440A1 (en) 2021-08-13 2022-08-09 Deuterated compounds

Publications (2)

Publication Number Publication Date
JP2024532807A true JP2024532807A (ja) 2024-09-10
JP2024532807A5 JP2024532807A5 (https=) 2026-02-27

Family

ID=85199822

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024508768A Pending JP2024532807A (ja) 2021-08-13 2022-08-09 重水素化化合物

Country Status (11)

Country Link
US (1) US20240270731A1 (https=)
EP (1) EP4384507A4 (https=)
JP (1) JP2024532807A (https=)
KR (1) KR20240047401A (https=)
CN (1) CN116848095B (https=)
AR (1) AR126778A1 (https=)
CA (1) CA3227149A1 (https=)
IL (1) IL310176A (https=)
MX (1) MX2024001889A (https=)
TW (1) TW202320762A (https=)
WO (1) WO2023016440A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118480034B (zh) * 2023-02-13 2025-02-11 礼邦医药(香港)有限公司 氘代化合物的晶型或盐
TW202547458A (zh) * 2024-03-26 2025-12-16 香港商禮邦醫藥（香港）有限公司 用於治療體染色體顯性多囊性腎病之方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60211891T2 (de) * 2001-05-15 2007-05-24 F. Hoffmann-La Roche Ag Carbonsäure-substituierte oxazol-derivate zur verwendung als ppar-alpha und -gamma aktivatoren zur behandlung von diabetes
US7262303B2 (en) * 2003-09-29 2007-08-28 Hoffman-La Roche Inc. Process for the production of chiral propionic acid derivatives
JP7618384B2 (ja) * 2017-02-21 2025-01-21 ジェンフィ Ｐｐａｒアゴニストとｆｘｒアゴニストとの組合せ
CN109265380A (zh) * 2017-10-18 2019-01-25 深圳市塔吉瑞生物医药有限公司 取代的丙-2-烯-1-酮化合物及其药物组合物
WO2020156683A1 (en) * 2019-02-01 2020-08-06 F. Hoffmann-La Roche Ag Aleglitazar for use in the treatment or prevention of major adverse cardiac events
CN112209896B (zh) * 2019-07-10 2023-05-16 苏州泽璟生物制药股份有限公司 噻唑烷二酮衍生物以及包含其的药物组合物
CN118480034B (zh) * 2023-02-13 2025-02-11 礼邦医药(香港)有限公司 氘代化合物的晶型或盐

Also Published As

Publication number Publication date
TW202320762A (zh) 2023-06-01
CA3227149A1 (en) 2023-02-16
AR126778A1 (es) 2023-11-15
US20240270731A1 (en) 2024-08-15
EP4384507A4 (en) 2025-06-18
CN116848095A (zh) 2023-10-03
EP4384507A1 (en) 2024-06-19
WO2023016440A1 (en) 2023-02-16
AU2022327461A1 (en) 2024-02-01
KR20240047401A (ko) 2024-04-12
CN116848095B (zh) 2024-05-24
MX2024001889A (es) 2024-02-29
IL310176A (en) 2024-03-01

Similar Documents

Publication Publication Date Title
JP2025131575A (ja) Ｍａｓ関連ｇタンパク質受容体ｘ４のモジュレーターおよび関連製品ならびに方法
AU781141B2 (en) Novel use of phenylheteroalkylamine derivatives
ES2603262T3 (es) Ácidos aminoindano-carboxílicos y aminotetralin-carboxílicos sustituidos y su uso
JP5425772B2 (ja) カルボン酸化合物
JP2024532807A (ja) 重水素化化合物
CN114981257A (zh) 取代的吡唑并哌啶羧酸
EP1613326A1 (en) (3-{3-´(2,4-bis-trifluormethyl-benzyl)-(5-ethyl-pyrimidin-2-yl)-amino!-propoxy}-phenyl)-acetic acid and related compounds as modulators of ppars and methods of treating metabolic disorders
EP3383388A1 (en) Aryl acylsulfonamides as blt1 antagonists
CN102307861B (zh) 苯基咪唑化合物
EP3383389A1 (en) Aryl acylsulfonamides as blt1 antagonists
CN118480034B (zh) 氘代化合物的晶型或盐
AU2022327461B2 (en) Deuterated compounds
JP2022542613A (ja) ヒトａｔｇｌの阻害剤
CN108069940B (zh) 硫代乙酸化合物、组合物及其应用
US5110821A (en) 1,3,4-oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents
HK40092869B (zh) 氘代化合物
HK40092869A (zh) 氘代化合物
CN112824394B (zh) PPARs-FXR多靶点小分子激动剂及其制备方法和用途
JP2010180183A (ja) 新規なピリミジン−４（３ｈ）−オン構造を有する化合物及びこれを含有する医薬
WO2010060277A1 (zh) 取代乙酰肼类衍生物及其制备方法和用途
TWI607995B (zh) 氮雜環衍生物及其在藥物中的應用
HK40073287A (en) Substituted pyrazolo piperidine carboxylic acids

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250624

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260218

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20260218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260421